Related Experiment Video

Updated: Jul 18, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Current stumbling blocks in oncology drug development

¹Global Pharma Development, Medical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Claude.Gimmi@Roche.com

Ernst Schering Research Foundation Workshop

|November 23, 2006

Abstract:

The prognosis of patients with metastatic cancer remains poor and treatment strategies including newer generations of chemotherapeutics have not significantly improved survival in most solid tumors. New approaches are required to further improve patient outcome and survival. Recently, a major leap in the understanding of the molecular mechanisms involved in signal transduction pathways that contribute to tumor growth have been identified as therapeutic targets. Particularly molecules involved in cellular proliferation (e.g., tyrosine kinases) and angiogenesis have been considered as targets for new treatment approaches. Novel therapeutics that specifically target kinase transduction pathways have shown promise as single agents and in combination with standard chemotherapy. In addition, results of recent studies with antiangiogenic monoclonal antibodies validate the use of this class of targeted therapeutics as an important new treatment modality in cancer. This review will focus on the drug development stumbling blocks of targeted treatment modalities in cancer.

Insights

Targeted cancer therapies show promise by inhibiting tumor growth pathways like tyrosine kinases and angiogenesis. However, drug development faces significant challenges for improving patient survival in metastatic cancers.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Metastatic cancer prognosis remains poor despite advances in chemotherapy.
Novel therapeutic strategies are needed to improve patient survival rates.
Understanding molecular pathways in tumor growth offers new therapeutic targets.

Purpose of the Study:

To review targeted treatment modalities for cancer.
To focus on drug development challenges for targeted therapies.
To discuss novel therapeutics targeting signal transduction pathways.

Main Methods:

Review of recent literature on targeted cancer therapies.
Analysis of molecular mechanisms in tumor growth and proliferation.
Evaluation of novel therapeutics including kinase inhibitors and monoclonal antibodies.

Main Results:

Targeted therapies, including tyrosine kinase inhibitors and antiangiogenic agents, show promise.
These novel therapeutics can be used as single agents or in combination with chemotherapy.
Antiangiogenic monoclonal antibodies represent an important new treatment modality.

Conclusions:

Targeted therapies offer a promising new avenue for cancer treatment.
Further research is needed to overcome drug development obstacles.
Improving patient outcomes in metastatic cancer requires innovative approaches.

Read full analysis

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Articles linked to this work by shared authors, journal, and citation graph.

Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy.

Cell death and differentiation·2001

Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model.

International journal of cancer·2001

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer.

International journal of cancer·1999

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells.

Nature medicine·1996

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

Proceedings of the National Academy of Sciences of the United States of America·1993

Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.

Blood·1993

See all related articles